載入...
Low-Dose Anti-Thymocyte Globulin (ATG) Preserves β-Cell Function and Improves HbA(1c) in New-Onset Type 1 Diabetes
OBJECTIVE: A pilot study suggested that combination therapy with low-dose anti-thymocyte globulin (ATG) and pegylated granulocyte colony-stimulating factor (GCSF) preserves C-peptide in established type 1 diabetes (T1D) (duration 4 months to 2 years). We hypothesized that 1) low-dose ATG/GCSF or 2)...
Na minha lista:
| 發表在: | Diabetes Care |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
American Diabetes Association
2018
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6105329/ https://ncbi.nlm.nih.gov/pubmed/30012675 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2337/dc18-0494 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|